This indicates the predictive power of PD-L2 is independent of PD-L1.70 Patients with PD-L1+ and PD-L2+ tumours (27.5%) had a stronger response than those with only PD-L1+ tumours (11.4%). The gene discussed is PDCD1LG2; the disease is neoplasm.